logo.png
Roche to present data from one of the most comprehensive oncology portfolios at the 2021 ASCO Annual Meeting showcasing advancements for people living with cancer
11 mai 2021 01h00 HE | F. Hoffmann-La Roche Ltd
Data from the first positive phase III study of a cancer immunotherapy in early, resected lung cancerStudies in personalised healthcare exploring tumour agnostic treatments that demonstrate the impact...
logo.png
Roche’s Tecentriq approved by European Commission as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer
05 mai 2021 01h00 HE | F. Hoffmann-La Roche Ltd
Tecentriq significantly improved overall survival in people with high PD-L1 expression, compared with chemotherapy in a Phase III studyTecentriq approval offers an alternative to chemotherapy for all...
logo.png
US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche’s Tecentriq for previously untreated metastatic bladder cancer
28 avr. 2021 16h00 HE | F. Hoffmann-La Roche Ltd
Basel, 28 April 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10 to 1 in favour of maintaining...
logo.png
Roche launches new ways to use their cardiovascular tests empowering clinicians to improve diagnosis and treatment of millions of people
28 avr. 2021 01h00 HE | F. Hoffmann-La Roche Ltd
Cardiovascular diseases are responsible for 17.9 million deaths every year¹, a third of all deaths globally²Roche announces five new intended uses for key cardiac biomarkers to help identify...
logo.png
US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche’s Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer
27 avr. 2021 18h25 HE | F. Hoffmann-La Roche Ltd
Basel, 28 April 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 7 to 2 in favour of maintaining...
logo.png
CHMP recommends EU approval of Roche’s ENSPRYNG (satralizumab) for adults and adolescents with neuromyelitis optica spectrum disorder (NMOSD)
23 avr. 2021 07h00 HE | F. Hoffmann-La Roche Ltd
If approved, ENSPRYNG will be the first and only treatment available to both adults and adolescents from 12 years of age with anti-aquaporin-4 antibody (AQP4-IgG) seropositive NMOSD in the EUENSPRYNG...
logo.png
Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy
23 avr. 2021 01h00 HE | F. Hoffmann-La Roche Ltd
About 90,000 women globally die from endometrial cancer each year1VENTANA MMR RxDx Panel is the first immunohistochemistry predictive test in endometrial cancer for treatment with the anti-PD1...
logo.png
Roche purchases shares in tender offer for GenMark Diagnostics, Inc.
22 avr. 2021 01h00 HE | F. Hoffmann-La Roche Ltd
Basel, 22 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and GenMark Diagnostics, Inc. today announced that Roche’s wholly owned subsidiary Geronimo Acquisition Corp. has accepted for payment all...
Roche reports solid results in the first quarter of 2021
21 avr. 2021 01h00 HE | F. Hoffmann-La Roche Ltd
Basel, 21 April 2021 Group sales increase 3%1 at constant exchange rates (CER); 1% decline in Swiss francs, as a result of the appreciation of the Swiss franc Pharmaceuticals Division sales:...
Roche fait état de solides résultats au premier trimestre 2021
21 avr. 2021 01h00 HE | F. Hoffmann-La Roche Ltd
Bâle, le 21 avril 2021 Le chiffre d’affaires consolidé progresse de 3%1 à taux de change constants (TCC), mais s’inscrit en baisse de 1% en francs suisses en raison de...